Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merck Raised Prices Of Five Drugs In November 2018, Including Keytruda

Merck & Co. Inc. raised U.S. prices on five of the company’s drugs in November 2018 by between 1.5 percent and 6 percent, including its top-selling cancer treatment Keytruda.

Read More »

Teva Issues Recall of Tainted Blood Pressure Medicine

Teva Pharmaceutical has issued a voluntary recall for combination forms of the company’s blood pressure drug amlodipine due to cancer-causing impurities discovered in the tablets.

Read More »

Top Predictions for 2019 by Biopharma Execs

Biopharma executives were asked to predict what the next year might reveal.

Read More »

Roche buys U.S. biotech Jecure in race for liver disease drugs

Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer, Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease.

Read More »

Jury clears J&J of liability in California talc cancer case

A California jury cleared J&J of liability in a case involving a woman who alleged that the company’s talc-based products – including its baby powder – contain asbestos and caused her cancer.

Read More »

Ribometrix Launches With $30 Million to Develop RNA Structure-Based Drugs

Durham, North Carolina-based Ribometrix closed on a Series A financing worth $30 million, led by M Ventures.

Read More »

Sobi buys rights to AstraZeneca infant drug

AstraZeneca took another step to refocus on priority drugs by selling U.S. rights to Synagis for infant lung infections to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion.

Read More »

Nestle raises stake in food allergy drug developer

Nestle’s health science arm will pay $98 million to raise its stake in Aimmune Therapeutics in preparation of submitting a marketing application for the peanut allergy drug AR101 by year-end 2018.

Read More »

AstraZeneca Q3 2018 drug sales turn corner

Strong demand for AstraZeneca’s new drugs – especially those for cancer – drove a return to sales growth in third-quarter 2018 and the drugmaker anticipates years of sustained improvement and rising profit margins.

Read More »

Health stocks up on U.S. vote, insurers hit records

Healthcare stocks rallied with U.S. health insurers reaching record highs as results of the 2018 mid-term elections were seen reducing the likelihood of action to cut medical costs and programs in the world’s biggest and most profitable market.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom